Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8% - Here's What Happened

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) shot up 6.8% during mid-day trading on Thursday . The company traded as high as $12.18 and last traded at $12.04. 181,621 shares were traded during trading, a decline of 72% from the average session volume of 644,293 shares. The stock had previously closed at $11.27.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. TD Cowen started coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a "buy" rating and a $35.00 price target on the stock. Evercore ISI raised Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday, September 27th. Finally, Oppenheimer raised their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and a consensus target price of $25.20.

Astria Therapeutics Stock Up 3.6 %

The business has a 50 day moving average of $11.55 and a 200 day moving average of $10.49. The firm has a market cap of $641.38 million, a price-to-earnings ratio of -5.03 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Research analysts predict that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Astria Therapeutics in the 3rd quarter worth about $155,000. Cubist Systematic Strategies LLC acquired a new position in Astria Therapeutics during the second quarter worth approximately $2,561,000. Nantahala Capital Management LLC purchased a new position in Astria Therapeutics during the second quarter worth approximately $6,142,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Astria Therapeutics in the 2nd quarter valued at $400,000. Finally, Millennium Management LLC grew its stake in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock valued at $16,763,000 after buying an additional 218,518 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.